171 related articles for article (PubMed ID: 31982573)
21. Solid lipid excipients - matrix agents for sustained drug delivery.
Rosiaux Y; Jannin V; Hughes S; Marchaud D
J Control Release; 2014 Aug; 188():18-30. PubMed ID: 24929038
[TBL] [Abstract][Full Text] [Related]
22. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
23. Manipulation of Pharmaceutical Polymorphic Transformation Process Using Excipients.
Tian B; Ding Z; Zong S; Yang J; Wang N; Wang T; Huang X; Hao H
Curr Pharm Des; 2020; 26(21):2553-2563. PubMed ID: 32053064
[TBL] [Abstract][Full Text] [Related]
24. Novel Thermal Imaging Method for Rapid Screening of Drug-Polymer Miscibility for Solid Dispersion Based Formulation Development.
Alhijjaj M; Belton P; Fábián L; Wellner N; Reading M; Qi S
Mol Pharm; 2018 Dec; 15(12):5625-5636. PubMed ID: 30372612
[TBL] [Abstract][Full Text] [Related]
25. Role of water in the physical stability of solid dosage formulations.
Airaksinen S; Karjalainen M; Shevchenko A; Westermarck S; Leppänen E; Rantanen J; Yliruusi J
J Pharm Sci; 2005 Oct; 94(10):2147-65. PubMed ID: 16136577
[TBL] [Abstract][Full Text] [Related]
26. Highly Viscoelastic Reverse Wormlike Micellar Systems from a Mixture of Lecithin, Polyglycerol Fatty Acid Monoesters, and an Oil.
Hashizaki K; Imai M; Yako S; Tsusaka H; Sakanishi Y; Saito Y; Fujii M
J Oleo Sci; 2017 Sep; 66(9):997-1007. PubMed ID: 28794316
[TBL] [Abstract][Full Text] [Related]
27. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
28. Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
Kasongo KW; Pardeike J; Müller RH; Walker RB
J Pharm Sci; 2011 Dec; 100(12):5185-96. PubMed ID: 22020815
[TBL] [Abstract][Full Text] [Related]
29. Reaction between drug substances and pharmaceutical excipients: formation of esters between cetirizine and polyols.
Yu H; Cornett C; Larsen J; Hansen SH
J Pharm Biomed Anal; 2010 Nov; 53(3):745-50. PubMed ID: 20627436
[TBL] [Abstract][Full Text] [Related]
30. Polyglycerol fatty acid ester surfactant-based microemulsions for targeted delivery of ceramide AP into the stratum corneum: formulation, characterisation, in vitro release and penetration investigation.
Sahle FF; Metz H; Wohlrab J; Neubert RH
Eur J Pharm Biopharm; 2012 Sep; 82(1):139-50. PubMed ID: 22691416
[TBL] [Abstract][Full Text] [Related]
31. Microstructure and stability of a lamellar liquid crystalline and gel phase formed by a polyglycerol ester mixture in dilute aqueous solution.
Duerr-Auster N; Kohlbrecher J; Zuercher T; Gunde R; Fischer P; Windhab E
Langmuir; 2007 Dec; 23(26):12827-34. PubMed ID: 18031069
[TBL] [Abstract][Full Text] [Related]
32. Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM).
Wolska E; Sznitowska M
Int J Pharm; 2013 Jan; 441(1-2):449-57. PubMed ID: 23164704
[TBL] [Abstract][Full Text] [Related]
33. Pure short-chain glycerol fatty acid esters and glycerylic cyclocarbonic fatty acid esters as surface active and antimicrobial coagels protecting surfaces by promoting superhydrophilicity.
Valentin R; Alignan M; Giacinti G; Renaud FN; Raymond B; Mouloungui Z
J Colloid Interface Sci; 2012 Jan; 365(1):280-8. PubMed ID: 21968402
[TBL] [Abstract][Full Text] [Related]
34. Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30.
Thybo P; Pedersen BL; Hovgaard L; Holm R; Mullertz A
Pharm Dev Technol; 2008; 13(5):375-86. PubMed ID: 18720236
[TBL] [Abstract][Full Text] [Related]
35. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
36. Solid lipid particles for oral delivery of peptide and protein drugs I--elucidating the release mechanism of lysozyme during lipolysis.
Christophersen PC; Zhang L; Yang M; Nielsen HM; Müllertz A; Mu H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):473-80. PubMed ID: 23911434
[TBL] [Abstract][Full Text] [Related]
37. Crystalline solid dispersion-a strategy to slowdown salt disproportionation in solid state formulations during storage and wet granulation.
Nie H; Xu W; Taylor LS; Marsac PJ; Byrn SR
Int J Pharm; 2017 Jan; 517(1-2):203-215. PubMed ID: 27979765
[TBL] [Abstract][Full Text] [Related]
38. Miscibility/stability considerations in binary solid dispersion systems composed of functional excipients towards the design of multi-component amorphous systems.
Yoo SU; Krill SL; Wang Z; Telang C
J Pharm Sci; 2009 Dec; 98(12):4711-23. PubMed ID: 19462469
[TBL] [Abstract][Full Text] [Related]
39. Solid lipid nanocarriers in drug delivery: characterization and design.
Mu H; Holm R
Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
[TBL] [Abstract][Full Text] [Related]
40. Molecularly designed lipid microdomains for solid dispersions using a polymer/inorganic carrier matrix produced by hot-melt extrusion.
Adler C; Schönenberger M; Teleki A; Kuentz M
Int J Pharm; 2016 Feb; 499(1-2):90-100. PubMed ID: 26721729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
